Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Search Results

Now showing 1 - 9 of 9
  • Item
    Efficacy and Safety of Diphenylcyclopropenone Alone or in Combination with Anthralin in the Treatment of Chronic Extensive Alopecia Areata: A Retrospective Case Series
    (2015) Durdu, Murat; Ozcan, Deren; Baba, Mete; Seckin, Deniz; 0000-0002-7450-6886; 0000-0003-1247-3932; 25653027; AAQ-6649-2021; H-9068-2019; HGU-2777-2022
    Background: Some patients with chronic extensive alopecia areata (AA) may be refractory to topical immunotherapy. Combination therapy is recommended for such patients. Efficacy and safety of a combination therapy with diphenylcyclopropenone (DPCP) and anthralin in chronic extensive AA is unknown. Objective: We sought to determine whether the combination therapy of DPCP and anthralin is superior to DPCP alone in chronic extensive AA. Methods: We retrospectively analyzed the efficacy, side effects, and relapse rates of DPCP (alone or with anthralin) in chronic extensive AA. Results: A total of 47 patients (22 were treated only with DPCP, and 25 with DPCP and anthralin for at least 30 weeks) were evaluated. Complete hair regrowth was observed in 36.4% and 72% of the patients who received DPCP and combination therapy, respectively (P = .01). Hair regrowth duration was shorter with combination therapy (P = .01). Regrowth rates of the eyebrows, eyelashes, and beard in patients on combination therapy were higher than those in patients on DPCP (P = .01). Side effects such as folliculitis, hyperpigmentation, and staining of skin, hair, and clothes were more common in combination therapy group. Limitations: The retrospective design and small number of patients are limitations. Conclusion: Combination therapy with DPCP and anthralin is superior to DPCP alone in chronic extensive AA.
  • Item
    Acquired Aquagenic Syringeal Acrokeratoderma: A Case Series of 10 Patients
    (2015) Erturk Ozdemir, Emel; Ozcan, Deren; Seckin, Deniz; 0000-0002-7450-6886; 24283504; AAQ-6649-2021
    Aquagenic syringeal acrokeratoderma is a rare acquired disorder that predominantly affects young women. It is most commonly localised on the palms. It is characterised by translucent papules, oedematous plaques and keratoderma developing after brief exposure to water and resolving shortly after drying. We have observed 10 patients with this disorder within 13 months. We think that aquagenic syringeal acrokeratoderma is a more common condition than was originally anticipated as one can easily underdiagnose this entity due to the transient nature of its clinical findings.
  • Item
    Eosinophilic Annular Erythema: A Late But Complete Response to Hydroxychloroquine
    (2017) Togral, Arzu Karatas; Seckin, Deniz; 26768795
    A 69-year-old woman with a 12-month history of asymptomatic erythematous, non-scaly, annular and arciform plaques on her face, trunk and extremities is presented. The skin lesions had been unresponsive to treatment with systemic corticosteroids and antihistamines. Skin biopsy demonstrated superficial and deep dermal inflammatory infiltration consisting mainly of eosinophils and a few neutrophils. Dermal interstitial mucin deposition was also detected in the absence of vasculitis, flame figures or granulomatous reaction. The patient was diagnosed as having eosinophilic annular erythema and treated with hydroxychloroquine (2x200mg/day, p.o.). Response to treatment was observed after 7weeks and full recovery was achieved after 10weeks. Eosinophilic annular erythema is rarely reported in the literature. Although hydroxychloroquine is a good choice for treatment, response time can vary between patients.
  • Item
    A Multicenter Survey: How Do Transplant Dermatologists Monitor Organ Transplant Recipients With Nevi?
    (2018) Ozcan, Deren; Seckin, Deniz; Haberal, Mehmet; 0000-0002-7450-6886; 0000-0002-3462-7632; 29528027; AAQ-6649-2021; AAJ-8097-2021
    Objectives: The incidence and mortality of melanoma are increased in organ transplant recipients. Multiple acquired common and dysplastic nevi are risk factors for melanoma. A new or changing nevus may suggest melanoma. Strategies used by transplant dermatologists to monitor nevi are unknown. Herein, we aimed to assess the methods used by transplant dermatologists for monitoring multiple acquired common nevi, dysplastic nevi, and new or changing nevi. Materials and Methods: A questionnaire was e-mailed to 63 members of the Skin Care in Organ Transplant Patients, Europe. Results: Thirty-eight (92.7%) of 41 responders reported that they instruct their patients to perform regular self-skin examinations. Of 41 responders, 41.5% prescribed screening every 6 months, 36.6% prescribed it every 12 months, 12.2% prescribed it every 3 months, and 9.7% performed screening without regular intervals. Regarding type of examination, 80.5% performed full-body skin examinations with the naked eye, 70.7% performed dermoscopy of clinically suspicious nevi, 53.6% offered dermoscopic photography of dermoscopically suspicious nevi, 36.6% provided close-up photography of clinically suspicious nevi, 34.1% performed baseline total body photography, and 24.4% conducted dermoscopy of all nevi. We also found that 7.3%, 4.9%, and 4.9% performed only full-body skin examination with the naked eye, only dermoscopy of clinically suspicious nevi, and only dermoscopy of all nevi, respectively. Conclusions: Dedicated transplant dermatologists perform a wide variety of nevi screening procedures in organ transplant recipients. Transplant dermatologists should include sequential digital dermoscopic imaging in their armamentarium to follow organ transplant recipients with melanocytic lesions. A combination of techniques is advisable for detecting early posttransplant melanomas.
  • Item
    Intralesional triamcinolone acetonide in notalgia paresthetica: Treatment outcomes in five patients
    (2020) Ozcan, Deren; Seckin, Deniz; Kibaroglu, Seda; Bernhard, Jeffrey D.; 0000-0002-7450-6886; 0000-0002-3964-268X; 32338414; AAQ-6649-2021; AAJ-2956-2021
    Numerous treatment modalities have been tried with diverse results for pruritus due to notalgia paresthetica (NP). Corticosteroids suppress ectopic neural discharges from injured nerve fibers and also have short-lived suppressive effect on transmission in normal C-fibers. Herein, we evaluated the efficacy of intralesional triamcinolone acetonide in the treatment of NP. The medical reports of five patients who had been diagnosed with NP and treated with intralesional triamcinolone acetonide injections were retrospectively evaluated. Triamcinolone acetonide solution was injected intradermally (10 mg/mL; 0.1 mL/cm(2)) every 3 weeks for a maximum of four treatments. The severity of itch was scored by the patients on a combined numerical and visual analogue scale. After treatment, reduction in itch severity scores varied between 33% and 100%.
  • Item
    CLINICAL CHARACTERISTICS AND OUTCOME OF HERPES ZOSTER IN SOLID ORGAN TRANSPLANT PATIENTS: A SINGLE CENTER CASE SERIES
    (2020) Altunel, Cemile Tugba; Seckin, Deniz; Sayin, Burak; Sezgin, Atilla; Akdur, Aydincan; Haberal, Mehmet A.
  • Item
    Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study
    (2019) Delyon, Julie; Rabate, Clementine; Euvrard, Sylvie; Harwood, Catherine A.; Proby, Charlotte; Gulec, Tulin; Seckin, Deniz; Del Marmol, Veronique; Bouwes-Bavinck, Jan Nico; Ferrandiz-Pulido, Carla; Ocampo, Maria Andrea; Barete, Stephane; Legendre, Christophe; Frances, Camille; Porcher, Raphael; Lebbe, Celeste; 30902727
    Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, or a combination of these. Objective: To obtain an overview of clinical strategies about the current treatment of KS. Methods: We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months. Results: Overall, 95%, 28%, and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor, and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. At 6 months, 83% of patients had response, including 40% complete responses. Limitations: The retrospective design of the study. Conclusion: Currently available therapeutic options seem to be effective to control KS in most patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.